Tenax Therapeutics (TENX) Accounts Payables (2011 - 2026)
Tenax Therapeutics (TENX) posted quarterly Accounts Payables of $6.8 million for Q2 2026, up 1109.07% year-over-year from $562000.0 in Q2 2025, and up 7.08% on a QoQ basis from $6.3 million in Q1 2026.
Tenax Therapeutics (TENX) Accounts Payables (2011 - 2026) Analysis & Trends
Tenax Therapeutics has reported Accounts Payables for 15 years, with the latest figure at $6.8 million in Q2 2026.
- Accounts Payables for Q2 2026 came in at $6.8 million, up 1109.07% year-over-year; the trailing twelve-month figure through Jun 2026 was $6.8 million (up 1109.07% YoY), and the FY2025 annual result was $6.0 million, up 91.35% from the prior year.
- Accounts Payables grew to $6.8 million in Q2 2026, from $6.3 million in the prior quarter.
- Over five years, Accounts Payables peaked at $6.8 million in Q2 2026 and troughed at $265407.0 in Q3 2022.
- A 5-year average of $2.2 million and a median of $1.2 million in 2022 frame the typical range for Accounts Payables.
- The widest annual swing landed in 2023, when Accounts Payables plunged 76.08%; it then surged 1109.07% in 2026.
- A 5-year view of Accounts Payables shows it stood at $775045.0 in 2022, then surged by 167.47% to $2.1 million in 2023, then soared by 52.29% to $3.2 million in 2024, then soared by 91.35% to $6.0 million in 2025, then grew by 12.48% to $6.8 million in 2026.
- Per Business Quant data, the three most recent Accounts Payables figures were $6.8 million in Q2 2026, $6.3 million in Q1 2026, and $6.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Tenax Therapeutics | 78.47 Mn | 78.47 Mn | - | 6.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.80 Mn |
| Mar 31, 2026 | 6.35 Mn |
| Dec 31, 2025 | 6.04 Mn |
| Sep 30, 2025 | 5.61 Mn |
| Jun 30, 2025 | 562,000.00 |
| Mar 31, 2025 | 1.84 Mn |
| Dec 31, 2024 | 3.16 Mn |
| Sep 30, 2024 | 977,545.00 |
| Jun 30, 2024 | 592,379.00 |
| Mar 31, 2024 | 536,443.00 |
| Dec 31, 2023 | 2.07 Mn |
| Sep 30, 2023 | 134,787.00 |
| Jun 30, 2023 | 271,633.00 |
| Mar 31, 2023 | 307,922.00 |
| Dec 31, 2022 | 775,045.00 |
| Sep 30, 2022 | 265,407.00 |
| Jun 30, 2022 | 919,384.00 |
| Mar 31, 2022 | 1.29 Mn |
| Dec 31, 2021 | 859,638.00 |
| Sep 30, 2021 | 776,247.00 |